CN104684389A - 含有天然专门促消退介质及其前体的具有抗炎活性的油 - Google Patents

含有天然专门促消退介质及其前体的具有抗炎活性的油 Download PDF

Info

Publication number
CN104684389A
CN104684389A CN201380036376.1A CN201380036376A CN104684389A CN 104684389 A CN104684389 A CN 104684389A CN 201380036376 A CN201380036376 A CN 201380036376A CN 104684389 A CN104684389 A CN 104684389A
Authority
CN
China
Prior art keywords
acid
carbon
oil
spm
pentaene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380036376.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·L·班南伯格
C·N·塞罕
F·莫雷诺埃热亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solutex NA LLC
Original Assignee
Solutex NA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104684389(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solutex NA LLC filed Critical Solutex NA LLC
Priority to CN202310172271.4A priority Critical patent/CN116173001A/zh
Priority to CN201910864506.XA priority patent/CN110478342A/zh
Publication of CN104684389A publication Critical patent/CN104684389A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380036376.1A 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油 Pending CN104684389A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310172271.4A CN116173001A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN201910864506.XA CN110478342A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645281P 2012-05-10 2012-05-10
US61/645,281 2012-05-10
PCT/US2013/040314 WO2013170006A2 (en) 2012-05-10 2013-05-09 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910864506.XA Division CN110478342A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN202310172271.4A Division CN116173001A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油

Publications (1)

Publication Number Publication Date
CN104684389A true CN104684389A (zh) 2015-06-03

Family

ID=49551457

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910864506.XA Pending CN110478342A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN202310172271.4A Pending CN116173001A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN201380036376.1A Pending CN104684389A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201910864506.XA Pending CN110478342A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油
CN202310172271.4A Pending CN116173001A (zh) 2012-05-10 2013-05-09 含有天然专门促消退介质及其前体的具有抗炎活性的油

Country Status (12)

Country Link
US (6) US10568858B2 (enExample)
EP (2) EP4205546A1 (enExample)
JP (2) JP6370775B2 (enExample)
CN (3) CN110478342A (enExample)
AU (1) AU2013259503B2 (enExample)
CA (1) CA2873055C (enExample)
DK (1) DK2858496T3 (enExample)
ES (1) ES2946109T3 (enExample)
NZ (1) NZ702325A (enExample)
PL (1) PL2858496T3 (enExample)
PT (1) PT2858496T (enExample)
WO (1) WO2013170006A2 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105120872A (zh) * 2013-01-30 2015-12-02 尊贵科学有限公司 包含15-ohepa的组合物以及其使用方法
CN108366600A (zh) * 2015-10-01 2018-08-03 索吕泰克斯纳有限公司 用于通过纤维素衍生物的等轴晶体网络制备和稳定具有ω-3的乳液的方法
CN108578398A (zh) * 2018-06-11 2018-09-28 温州医科大学 巨噬素在制备预防或治疗类风湿性关节炎的药物中的应用
CN110325185A (zh) * 2017-01-18 2019-10-11 巴塞罗那自治大学 用于治疗神经退行性疾病和/或自身免疫性疾病的专门的促消退脂质介质
CN110420224A (zh) * 2019-07-25 2019-11-08 江苏华豚药业有限公司 河豚肝油皂化物的应用及其制备方法
CN112912054A (zh) * 2018-10-24 2021-06-04 株式会社爱茉莉太平洋 皮肤屏障强化用组合物
CN112912053A (zh) * 2018-10-15 2021-06-04 株式会社爱茉莉太平洋 皮肤屏障强化用组合物
CN114144192A (zh) * 2019-08-01 2022-03-04 赢创运营有限公司 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂
CN115038434A (zh) * 2019-12-09 2022-09-09 路易斯安娜州立大学监测委员会，农业和机械学院 用于治疗角膜病变的生物分子
CN116139122A (zh) * 2023-02-28 2023-05-23 武汉大学人民医院（湖北省人民医院） 消退素d2在制备缓解和/或治疗心肌梗死及其相关疾病的药物中的应用
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
AU2014272044B2 (en) * 2013-05-30 2019-11-07 The Brigham & Women's Hospital Inc. Novel n-3 immunoresolvents: structures and actions
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CA2935986A1 (en) * 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
JP6315536B2 (ja) * 2014-01-29 2018-04-25 岩手県 Ｐｐａｒ活性化剤
JP6604529B2 (ja) * 2014-01-29 2019-11-13 岩手県 ヒドロキシエイコサペンタエン酸の取得方法
EP3906920A1 (en) 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1247136A1 (zh) * 2015-01-16 2018-09-21 Afimmune Limited 包含15-hepe的组合物和其使用方法
JP7025212B2 (ja) 2015-02-09 2022-02-24 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
KR20170122808A (ko) 2015-03-10 2017-11-06 이엘씨 매니지먼트 엘엘씨 염증을 해소하도록 피부를 치료하고 해소촉진 경로를 자극하는 활성성분에 대해 스크리닝하기 위한 방법 및 조성물
EP3861995A1 (en) * 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
WO2017210604A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
US11583511B2 (en) 2017-07-20 2023-02-21 Universitat Autonoma De Barcelona Maresins for use in the treatment of CNS injuries
KR101981534B1 (ko) * 2017-09-01 2019-05-23 (주)솔빛피앤에프 프로텍틴 dx를 유효성분으로 함유하는 고지혈증 또는 지방간 질환 예방 또는 치료용 조성물
KR102003153B1 (ko) * 2018-01-17 2019-07-23 연세대학교 산학협력단 레졸빈 d2를 유효성분으로 함유하는 피부 염증 치료용 조성물
CN111989399B (zh) 2018-04-16 2024-07-12 韩国生命工学研究院 多不饱和脂肪酸的多羟基衍生物的制备方法
NO345574B1 (en) 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
WO2019243887A1 (en) 2018-06-22 2019-12-26 Ambiotis Method for restoration of the natural capacity of the body to end inflammation by personalization of the food supplementation and objectification of its effect
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
US11400057B2 (en) 2018-10-19 2022-08-02 University Of Rochester Treatment of vulvar pain
US20210393565A1 (en) * 2018-11-30 2021-12-23 Evonik Operations Gmbh Preparation for use to increase the formation of one or more specialized pro-resolving lipid mediators (spm)
WO2020252413A1 (en) * 2019-06-13 2020-12-17 The Regents Of The University Of California Methods and compositions for determination liver fibrosis
US11607623B2 (en) 2019-08-08 2023-03-21 Cornerstone Technologies Llc Dynamic interface system and its application in supercritical fluid extraction and chromatography
GB201913383D0 (en) * 2019-09-17 2019-10-30 Univ London Queen Mary Methods for predicting patient response to DMARDs
KR102870005B1 (ko) * 2019-09-25 2025-10-17 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR102256823B1 (ko) * 2019-12-06 2021-05-26 한국생명공학연구원 도코사헥사노엔산 유도체를 함유하는 주름 개선, 아토피피부염 개선 및 피부 장벽 강화용 복합 조성물
EP4071241A4 (en) * 2019-12-06 2023-10-18 Korea Research Institute of Bioscience and Biotechnology MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PROCESS FOR THEIR PRODUCTION AND USE
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2022013478A1 (es) 2020-07-17 2022-01-20 Solutex Gc, S. L. Método diagnóstico y compuestos para el tratamiento de infecciones causadas por un patógeno
WO2022049168A1 (en) * 2020-09-04 2022-03-10 Dsm Ip Assets B.V. 17(s)-hdpa for metabolic-syndrome related disorders
MX2023006157A (es) 2020-12-04 2023-06-08 Chemo Res S L Mediadores lipidicos proresolutivos especializados para el tratamiento del pcos.
KR102662544B1 (ko) * 2021-10-19 2024-05-03 서울대학교산학협력단 참문어 추출물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물
WO2023180569A1 (en) 2022-03-25 2023-09-28 Chemo Research , S.L. Specialized pro-resolving lipid mediators for treating long covid-19
CN115466776B (zh) * 2022-09-26 2025-06-27 中国医学科学院基础医学研究所 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物
WO2025233510A1 (en) 2024-05-10 2025-11-13 Chemo Research, S.L. Specialized pro-resolving lipid mediators for treating depression, anxiety, and/or stress

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1469858A (zh) * 2000-02-16 2004-01-21 �����ķ����ŮҽԺ�ɷ����޹�˾ 阿司匹林触发的脂质介体
CN101102988A (zh) * 2004-11-19 2008-01-09 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US20110288317A1 (en) * 2008-09-16 2011-11-24 The Brigham and Women"s Hosptial Inc. 14-hydroxy-docosahexaenoic acid compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH01169354A (ja) * 1987-12-25 1989-07-04 Hitachi Ltd 超臨界炭酸ガス抽出物の分取方法
US4966876A (en) 1989-08-22 1990-10-30 Viswanatha Sankaran Transesterification of triglycerides
US5133902A (en) 1989-08-22 1992-07-28 Viswanatha Sankaran Transesterification of triglycerides
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
KR100234947B1 (ko) 1997-06-05 1999-12-15 이형도 멀티 탭 고주파 모듈레이터
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
JP4175698B2 (ja) * 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
JPWO2002102364A1 (ja) * 2001-06-18 2004-09-30 山田　幸子 ＰＰＡＲγ作動性医薬組成物
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
JPWO2004048497A1 (ja) 2002-11-22 2006-03-30 日本水産株式会社 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP4280158B2 (ja) * 2002-12-27 2009-06-17 富士フイルム株式会社 ドコサヘキサエン酸生産能を有する微生物及びその利用
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
MX374545B (es) * 2007-06-29 2025-03-06 Dsm Ip Assets Bv Produccion y purificacion de esteres de acidos grasos poliinsaturados.
CN103168860A (zh) 2007-08-31 2013-06-26 马太克生物科学公司 含多不饱和脂肪酸的固体脂肪组合物及其制备与应用
US8853437B2 (en) 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
US20110071090A1 (en) 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
CL2009001343A1 (es) * 2009-06-02 2009-07-10 Golden Omega S A Proceso de obtencion concentrado de esteres de epa y dha a partir de aceite marino, que comprende agregar al aceite alcali y agua a menos de 100 grados celsius, agregar solvente, separar fase de refinado, agregar acido, separar la fase no acuosa y agregar alcohol y un catalizador a menos de 150 grados celsius, desolventilizar y destilar.
US8479921B2 (en) 2009-12-09 2013-07-09 Amcor Flexibles, Inc. Child resistant blister package
US20110178105A1 (en) 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
JP5909183B2 (ja) 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US10383839B2 (en) 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
PH12021552871A1 (en) 2011-12-27 2022-09-28 Commw Scient Ind Res Org Processes for producing lipids
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
US10130601B2 (en) 2013-06-27 2018-11-20 Smartfish As Use of a composition comprising fish oil and juice for the treatment of inflammation
CA2935986A1 (en) 2014-01-10 2015-07-16 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1469858A (zh) * 2000-02-16 2004-01-21 �����ķ����ŮҽԺ�ɷ����޹�˾ 阿司匹林触发的脂质介体
CN101102988A (zh) * 2004-11-19 2008-01-09 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US20110288317A1 (en) * 2008-09-16 2011-11-24 The Brigham and Women"s Hosptial Inc. 14-hydroxy-docosahexaenoic acid compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAREN J M ET AL: "Fatty acid and sterol composition of frozen and freeze-dried New Zealand Green Lipped Mussel (Perna canaliculus) from three sites in New Zealand", 《ASIA PACIFIC J CLIN. NUTR.》 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214464A (zh) * 2013-01-30 2020-06-02 Af免疫有限公司 包含15-hepe的组合物以及其使用方法
CN105120872A (zh) * 2013-01-30 2015-12-02 尊贵科学有限公司 包含15-ohepa的组合物以及其使用方法
CN108366600A (zh) * 2015-10-01 2018-08-03 索吕泰克斯纳有限公司 用于通过纤维素衍生物的等轴晶体网络制备和稳定具有ω-3的乳液的方法
CN108366600B (zh) * 2015-10-01 2022-04-29 索吕泰克斯纳有限公司 用于通过纤维素衍生物的等轴晶体网络制备和稳定具有ω-3的乳液的方法
CN110325185A (zh) * 2017-01-18 2019-10-11 巴塞罗那自治大学 用于治疗神经退行性疾病和/或自身免疫性疾病的专门的促消退脂质介质
CN108578398A (zh) * 2018-06-11 2018-09-28 温州医科大学 巨噬素在制备预防或治疗类风湿性关节炎的药物中的应用
CN112912053A (zh) * 2018-10-15 2021-06-04 株式会社爱茉莉太平洋 皮肤屏障强化用组合物
CN112912054A (zh) * 2018-10-24 2021-06-04 株式会社爱茉莉太平洋 皮肤屏障强化用组合物
US12447117B2 (en) 2018-10-24 2025-10-21 Amorepacific Corporation Composition and method of enhancing skin barrier using the same
CN110420224A (zh) * 2019-07-25 2019-11-08 江苏华豚药业有限公司 河豚肝油皂化物的应用及其制备方法
CN114144192A (zh) * 2019-08-01 2022-03-04 赢创运营有限公司 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂
CN118252869A (zh) * 2019-08-01 2024-06-28 赢创运营有限公司 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂
CN115038434A (zh) * 2019-12-09 2022-09-09 路易斯安娜州立大学监测委员会，农业和机械学院 用于治疗角膜病变的生物分子
US12337049B2 (en) 2021-05-26 2025-06-24 Amorepacific Corporation Method for whitening skin using composition for skin whitening
CN116139122A (zh) * 2023-02-28 2023-05-23 武汉大学人民医院（湖北省人民医院） 消退素d2在制备缓解和/或治疗心肌梗死及其相关疾病的药物中的应用

Also Published As

Publication number Publication date
US11077084B2 (en) 2021-08-03
EP2858496B9 (en) 2023-11-29
CN110478342A (zh) 2019-11-22
CA2873055C (en) 2023-10-10
US10568858B2 (en) 2020-02-25
JP6821626B2 (ja) 2021-01-27
US11865096B2 (en) 2024-01-09
EP2858496A4 (en) 2016-03-23
WO2013170006A2 (en) 2013-11-14
AU2013259503A1 (en) 2014-12-18
US20180271818A1 (en) 2018-09-27
US11285126B2 (en) 2022-03-29
JP2018193378A (ja) 2018-12-06
CA2873055A1 (en) 2013-11-14
WO2013170006A3 (en) 2014-01-03
US20220175711A1 (en) 2022-06-09
EP4205546A1 (en) 2023-07-05
US20150126602A1 (en) 2015-05-07
JP2015522535A (ja) 2015-08-06
EP2858496B1 (en) 2023-04-12
US20200281883A1 (en) 2020-09-10
JP6370775B2 (ja) 2018-08-08
PT2858496T (pt) 2023-07-20
US20190201363A1 (en) 2019-07-04
NZ702325A (en) 2016-09-30
DK2858496T3 (da) 2023-07-24
US11077083B2 (en) 2021-08-03
EP2858496A2 (en) 2015-04-15
CN116173001A (zh) 2023-05-30
AU2013259503B2 (en) 2017-03-16
ES2946109T3 (es) 2023-07-12
PL2858496T3 (pl) 2023-09-11
US20210154163A1 (en) 2021-05-27
WO2013170006A4 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
US11865096B2 (en) Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11648229B2 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
JP2023107827A (ja) 水産物由来遊離１価不飽和脂肪酸又はその低級アルコールエステルの製造方法
WO2024043787A1 (en) Cetoleic acid composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150603

RJ01 Rejection of invention patent application after publication